A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee
Phase 2
Completed
- Conditions
- Osteoarthritis of the KneeChronic Lower Back Pain
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 215
- Registration Number
- NCT02611466
- Locations
- π§πͺ
Site BE32003, Leuven, Belgium
π§πͺSite BE32002, Merksem, Belgium
π§πͺSite BE32004, Yvoir, Belgium
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
Phase 1
Completed
- Conditions
- Neurogenic Detrusor OveractivityOveractive Bladder
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 9
- Registration Number
- NCT02526979
- Locations
- π©π°
Site DK45002, Aalborg, Denmark
π©π°Site DK45001, Aarhus, Denmark
π΅π±Site PL48001, Warsaw, Poland
A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 12
- Registration Number
- NCT02447315
- Locations
- π¬π§
PAREXEL Early Phase Clinical Unit, Harrow, United Kingdom
First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 116
- Registration Number
- NCT02420782
- Locations
- π©πͺ
Site DE49001, Berlin, Germany
π¬π§Site GB44001, Harrow, United Kingdom
A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects
Phase 1
Completed
- Conditions
- Pharmacodynamics of ASP1707Pharmacokinetics of ASP1707
- Interventions
- Drug: ASP1707 multiple dose of dose levels 1-4Drug: ASP1707 parallel multiple dose of dose levels 1-3Drug: ASP1707 single dose of dose levels 1 -7Drug: Placebo single dose of dose levels 1-7Drug: ASP1707 single dose fastedDrug: ASP1707 single dose fedDrug: Placebo multiple dose of dose levels 1-4Drug: Placebo multiple dose of dose levels 1-2Drug: ASP1707 multiple dose of dose levels 1-2Drug: Placebo parallel multiple dose
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 176
- Registration Number
- NCT02368912
- Locations
- π«π·
SGS Life Science Services, Aster, Paris, France
A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 88
- Registration Number
- NCT02359032
- Locations
- π¬π§
Site GB44001, Harrow, United Kingdom
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
Phase 2
Completed
- Conditions
- Chronic Kidney DiseaseType 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 125
- Registration Number
- NCT02358096
- Locations
- π¨πΏ
Site CZ42002, Brno, Czechia
π¨πΏSite CZ42003, CeskΓ© Budejovice, Czechia
π¨πΏSite CZ42001, Prague 4, Czechia
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205
Phase 1
Terminated
- Conditions
- Pharmacokinetics of ASP2205Healthy Subjects
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 93
- Registration Number
- NCT02314793
- Locations
- π¬π§
Site GB44001, Harrow, United Kingdom
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
Phase 2
Completed
- Conditions
- Diabetes MellitusDiabetic Macular Edema
- Interventions
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 96
- Registration Number
- NCT02302079
- Locations
- πΊπΈ
Site US10021, Phoenix, Arizona, United States
πΊπΈSite US10025, Tucson, Arizona, United States
πΊπΈSite US10006, Arcadia, California, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects
Phase 1
Withdrawn
- Conditions
- Pharmacokinetics of ASP3700Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Registration Number
- NCT02285465